Arvinas (ARVN) Competitors $18.05 +0.47 (+2.67%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARVN vs. TGTX, VKTX, AXSM, KRYS, OGN, SRRK, ALVO, ADMA, RARE, and VRNAShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. TG Therapeutics Viking Therapeutics Axsome Therapeutics Krystal Biotech Organon & Co. Scholar Rock Alvotech ADMA Biologics Ultragenyx Pharmaceutical Verona Pharma TG Therapeutics (NASDAQ:TGTX) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Does the MarketBeat Community favor TGTX or ARVN? TG Therapeutics received 473 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 76.42% of users gave TG Therapeutics an outperform vote while only 67.03% of users gave Arvinas an outperform vote. CompanyUnderperformOutperformTG TherapeuticsOutperform Votes65876.42% Underperform Votes20323.58% ArvinasOutperform Votes18567.03% Underperform Votes9132.97% Does the media prefer TGTX or ARVN? In the previous week, TG Therapeutics had 26 more articles in the media than Arvinas. MarketBeat recorded 28 mentions for TG Therapeutics and 2 mentions for Arvinas. TG Therapeutics' average media sentiment score of 0.72 beat Arvinas' score of 0.14 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 9 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend TGTX or ARVN? TG Therapeutics presently has a consensus price target of $40.67, suggesting a potential upside of 37.62%. Arvinas has a consensus price target of $63.50, suggesting a potential upside of 251.80%. Given Arvinas' stronger consensus rating and higher probable upside, analysts clearly believe Arvinas is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Arvinas 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has more risk and volatility, TGTX or ARVN? TG Therapeutics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.87, indicating that its share price is 87% more volatile than the S&P 500. Which has higher valuation & earnings, TGTX or ARVN? TG Therapeutics has higher revenue and earnings than Arvinas. TG Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$233.66M19.69$12.67M-$0.10-295.47Arvinas$78.50M15.80-$367.30M-$4.67-3.87 Do institutionals & insiders hold more shares of TGTX or ARVN? 58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 10.5% of TG Therapeutics shares are owned by insiders. Comparatively, 5.2% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TGTX or ARVN more profitable? Arvinas has a net margin of 0.00% compared to TG Therapeutics' net margin of -5.42%. TG Therapeutics' return on equity of -8.32% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics-5.42% -8.32% -3.40% Arvinas N/A -50.26%-24.87% SummaryTG Therapeutics beats Arvinas on 12 of the 18 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$6.23B$5.21B$9.15BDividend YieldN/A2.94%5.13%4.03%P/E Ratio-3.879.4687.9017.36Price / Sales15.80310.131,245.5478.03Price / CashN/A61.4443.7535.97Price / Book1.516.055.314.79Net Income-$367.30M$154.90M$122.62M$225.00M7 Day Performance0.22%-0.32%0.58%2.62%1 Month Performance-2.33%0.43%2.54%3.81%1 Year Performance-50.44%3.08%25.49%20.10% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas2.5327 of 5 stars$18.05+2.7%$63.50+251.8%-50.4%$1.24B$78.50M-3.87420TGTXTG Therapeutics4.4757 of 5 stars$27.76-3.9%$40.67+46.5%+96.1%$4.32B$264.79M-277.57290Analyst RevisionVKTXViking Therapeutics3.9434 of 5 stars$38.61-1.8%$106.75+176.5%+50.0%$4.30BN/A-41.5220Analyst ForecastAXSMAxsome Therapeutics4.6768 of 5 stars$88.47+10.5%$129.43+46.3%+8.2%$4.29B$338.46M-13.55380Analyst RevisionKRYSKrystal Biotech4.8908 of 5 stars$147.78-3.4%$206.67+39.8%+15.5%$4.25B$241.52M83.49229Short Interest ↓OGNOrganon & Co.4.7928 of 5 stars$15.56-1.8%$21.33+37.1%+1.7%$4.01B$6.41B3.0910,000Positive NewsSRRKScholar Rock2.9878 of 5 stars$42.66+5.4%$40.43-5.2%+186.4%$3.99B$33.19M-18.15140ALVOAlvotech2.7886 of 5 stars$13.20-2.4%$18.00+36.4%-6.2%$3.98B$391.87M-7.141,026Positive NewsADMAADMA Biologics4.0452 of 5 stars$16.79-9.5%$21.25+26.6%+219.8%$3.97B$382.81M59.96530Short Interest ↑Gap DownRAREUltragenyx Pharmaceutical4.6475 of 5 stars$42.56+1.2%$92.29+116.8%-10.3%$3.93B$522.75M-6.581,276Analyst RevisionVRNAVerona Pharma2.0679 of 5 stars$46.68+3.3%$50.57+8.3%+202.2%$3.75B$5.62M-24.3130 Related Companies and Tools Related Companies TGTX Competitors VKTX Competitors AXSM Competitors KRYS Competitors OGN Competitors SRRK Competitors ALVO Competitors ADMA Competitors RARE Competitors VRNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARVN) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
